

Resource Summary Report

Generated by [dkNET](#) on Aug 17, 2026

APC anti-human MICA/MICB

RRID:AB_493195

Type: Antibody

Proper Citation

BioLegend Cat# 320908, RRID:AB_493195

Antibody Information

URL: http://antibodyregistry.org/AB_493195

Proper Citation: BioLegend Cat# 320908, RRID:AB_493195

Target Antigen: MICA MICB

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human MICA/MICB

Description: This monoclonal targets MICA MICB

Target Organism: human

Clone ID: Clone 6D4

Antibody ID: AB_493195

Vendor: BioLegend

Catalog Number: 320908

Alternative Catalog Numbers: 320907

Record Creation Time: 20250819T231203+0000

Record Last Update: 20250820T043605+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human MICA/MICB.

No alerts have been found for APC anti-human MICA/MICB.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Li YR, et al. (2025) Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells. Cell reports. Medicine, 6(9), 102321.

Li YR, et al. (2025) Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays. STAR protocols, 6(2), 103742.

Mensching L, et al. (2025) HIV-1 infection of macrophages differentially primes NK-cell cytotoxicity and proinflammatory cytokine production. iScience, 28(7), 112879.

Li YR, et al. (2025) Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med (New York, N.Y.), 100804.

Li YR, et al. (2023) Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. iScience, 26(10), 107952.

van Vliet AA, et al. (2023) Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34+ progenitor cell-derived NK cells. iScience, 26(7), 107078.

Goulding J, et al. (2023) A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors. Med (New York, N.Y.), 4(7), 457.